Immunogenicity of two different dosages (10 and 5 μg) of recombinant DNA hepatitis B vaccine in healthy neonates
- 31 December 1994
- Vol. 12 (14) , 1323-1326
- https://doi.org/10.1016/s0264-410x(94)80059-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Immunogenicity of 20 μg of recombinant DNA hepatitis B vaccine in healthy neonates: A comparison of three different vaccination schemesJournal of Medical Virology, 1993
- Comparison of the immunogenicity of reduced doses of two recombinant dna hepatitis b vaccines in New Zealand childrenJournal of Medical Virology, 1989
- Persistence of specific antibodies after hepatitis B vaccinationJournal of Hepatology, 1988
- Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmissionJAMA, 1987
- Use of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: Two doses vs. three doses of 5 μg regime; an interim reportJournal of Infection, 1986
- Long-Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Homosexual MenNew England Journal of Medicine, 1986
- Safety and immunogenicity of a recombinant hepatitis B vaccineJournal of Medical Virology, 1985
- Human hepatitis B vaccine from recombinant yeastNature, 1984
- A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final reportHepatology, 1981
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976